Here are the 424B prospectus supplements from Oncolytics Biotech, Inc. (ONCY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ONCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONCY filings page.
Oncolytics Biotech Inc. has filed a prospectus supplement to offer up to $75,000,000 of common stock through an at-the-market sales agreement with Jefferies LLC. Sales may occur from time to time at market prices; Jefferies may act as agent or principal and may earn commissions up to 3.0%.
The company states net proceeds will be used to fund clinical development of pelareorep, R&D, operating costs and general corporate purposes. The prospectus cites 108,021,271 shares outstanding as of December 31, 2025 and presents a pro forma example (sale of 78,125,000 shares at $0.96) producing up to 186,146,271 shares outstanding.